Oxford/AstraZeneca (AZN) vaccine data looks 'mediocre' - STAT's Feuerstein
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mail
Get Alerts AZN Hot Sheet
Join SI Premium – FREE
Oxford/AstraZeneca (NYSE: AZN) vaccine data looks "mediocre", STAT's Adam Feuerstein said on Twitter.
I am NOT a vaccine expert but the Oxford $AZN data look mediocre to me — disappointing relative to all the hype coming into Monday.
— Adam Feuerstein (@adamfeuerstein) July 20, 2020
Is this how others more knowledgable than me see it, too?
What am I missing here?
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) spreader of 11694 contracts of October 170, January 180 and January 210 calls as share price up 3.2%
- AstraZeneca partners with insitro on AI-driven cardiometabolic drug discovery
- Dream Finders Holdings (DFH) Mentioned Cautiously at Bear Cave
Create E-mail Alert Related Categories
FDA, Trader TalkRelated Entities
Twitter, Adam FeuersteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
